E-mail: Cardiovascular toxicity, a prominent reason for late-stage failures in drug development, has resulted in a demand for in vitro assays that can predict this liability in early drug discovery. Current in vitro cardiovascular safety testing primarily focuses on ion channel modulation and low throughput cardiomyocyte contractility measurements.
http://ift.tt/1y9VjkY
http://ift.tt/1y9VjkY
No comments:
Post a Comment